The lawsuit, spearheaded by the Rosen Law Firm, alleges that Regencell misled shareholders by concealing the company's susceptibility to market volatility. According to the complaint, these omissions exposed investors to substantial financial risk and increased the likelihood of regulatory scrutiny. The filing claims that when the reality of these risks surfaced, the stock's performance caused direct financial harm to those who purchased securities during the specified Class Period.
In section Releases
Regencell Investors Face June 23 Deadline in Securities Fraud Lawsuit
Investors who lost significant capital trading Regencell Bioscience Holdings Limited shares between October 2024 and October 2025 have until June 23, 2026, to file as lead plaintiffs in a pending class action lawsuit. The case centers on allegations that the company failed to disclose vulnerabilities to market manipulation.
Investors with losses exceeding $100,000 are currently being sought to serve as lead plaintiffs to represent the class. While the firm encourages participants to secure experienced legal representation, it notes that no class has been formally certified yet. Until certification occurs, individuals remain responsible for retaining their own counsel or opting to stay as absent class members. Those interested in joining the litigation or seeking further information may contact Phillip Kim at the Rosen Law Firm via their online submission portal or by phone.
Comments (0)
No comments yet. Be the first!